351
|
Shi Y, van der Meel R, Theek B, Blenke EO, Pieters EH, Fens MH, Ehling J, Schiffelers RM, Storm G, van Nostrum CF, Lammers T, Hennink WE. Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π-Π Stacking Stabilized Polymeric Micelles. ACS NANO 2015; 9:3740-52. [PMID: 25831471 PMCID: PMC4523313 DOI: 10.1021/acsnano.5b00929] [Citation(s) in RCA: 162] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Treatment of cancer patients with taxane-based chemotherapeutics, such as paclitaxel (PTX), is complicated by their narrow therapeutic index. Polymeric micelles are attractive nanocarriers for tumor-targeted delivery of PTX, as they can be tailored to encapsulate large amounts of hydrophobic drugs and achiv prolonged circulation kinetics. As a result, PTX deposition in tumors is increased, while drug exposure to healthy tissues is reduced. However, many PTX-loaded micelle formulations suffer from low stability and fast drug release in the circulation, limiting their suitability for systemic drug targeting. To overcome these limitations, we have developed PTX-loaded micelles which are stable without chemical cross-linking and covalent drug attachment. These micelles are characterized by excellent loading capacity and strong drug retention, attributed to π-π stacking interaction between PTX and the aromatic groups of the polymer chains in the micellar core. The micelles are based on methoxy poly(ethylene glycol)-b-(N-(2-benzoyloxypropyl)methacrylamide) (mPEG-b-p(HPMAm-Bz)) block copolymers, which improved the pharmacokinetics and the biodistribution of PTX, and substantially increased PTX tumor accumulation (by more than 2000%; as compared to Taxol or control micellar formulations). Improved biodistribution and tumor accumulation were confirmed by hybrid μCT-FMT imaging using near-infrared labeled micelles and payload. The PTX-loaded micelles were well tolerated at different doses, while they induced complete tumor regression in two different xenograft models (i.e., A431 and MDA-MB-468). Our findings consequently indicate that π-π stacking-stabilized polymeric micelles are promising carriers to improve the delivery of highly hydrophobic drugs to tumors and to increase their therapeutic index.
Collapse
Affiliation(s)
- Yang Shi
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| | - Roy van der Meel
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Benjamin Theek
- Department of Experimental Molecular Imaging (ExMI), Helmholtz Institute for Biomedical Engineering, RWTH Aachen University Clinic, Aachen, Germany
| | - Erik Oude Blenke
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| | - Ebel H.E. Pieters
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| | - Marcel H.A.M. Fens
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Josef Ehling
- Department of Experimental Molecular Imaging (ExMI), Helmholtz Institute for Biomedical Engineering, RWTH Aachen University Clinic, Aachen, Germany
| | - Raymond M. Schiffelers
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
- Department of Controlled Drug Delivery, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Cornelus F. van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| | - Twan Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
- Department of Experimental Molecular Imaging (ExMI), Helmholtz Institute for Biomedical Engineering, RWTH Aachen University Clinic, Aachen, Germany
- Department of Controlled Drug Delivery, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Wim E. Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
352
|
Mérian J, Boisgard R, Bayle PA, Bardet M, Tavitian B, Texier I. Comparative biodistribution in mice of cyanine dyes loaded in lipid nanoparticles. Eur J Pharm Biopharm 2015; 93:1-10. [PMID: 25805562 DOI: 10.1016/j.ejpb.2015.03.019] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Revised: 03/13/2015] [Accepted: 03/16/2015] [Indexed: 12/14/2022]
Abstract
Two near infrared cyanine dyes, DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine perchlorate) and ICG (Indocyanine Green) were loaded in lipid nanoparticles (LNP). DiD-LNP and ICG-LNP presented similar physicochemical characteristics (hydrodynamic diameter, polydispersity, zeta potential), encapsulation efficiency, and colloidal stability when stored in PBS buffer. However, whereas DiD had similar biodistribution than cholesteryl-1-(14)C-oleate ([(14)C]CHO, a constituent of the nanoparticle used as a reference radiotracer), ICG displayed a different biodistribution pattern, similar to that of the free dye, indicative of its immediate leakage from the nanovector after blood injection. NMR spectroscopy using Proton NOE (Nuclear Overhauser Effect) measurements showed that the localization of the dye in the lipid nanoparticles was slightly different: ICG, more amphiphilic than DiD, was found both inside the lipid core and at particle interface, whereas DiD, more hydrophobic, appeared exclusively located inside the particle core. The ICG release rate from the particles was 7% per 1 month under storage conditions (4 °C, dark, 10% of lipids), whereas no leakage could be detected for DiD. ICG leakage increased considerably in the presence of BSA 40 g/L (45% leakage in 24h at 100 mg/mL of lipids), because of the high affinity of the fluorophore for plasma proteins. On the contrary, no DiD leakage was observed, until high dilution of the nanoparticles which triggered their dissociation (45% leakage in 24h at 1 mg/mL of lipids). Altogether, the subtle difference in dye localization into the nanoparticles, the partial dissociation of the LNP in diluted media, and more importantly the high ICG affinity for plasma proteins, accounted for the differences observed in the fluorescence biodistribution after tail vein injection of the dye-loaded nanoparticles.
Collapse
Affiliation(s)
- Juliette Mérian
- Université Grenoble Alpes, F-38000 Grenoble, France; CEA-LETI MINATEC/ DTBS, 17 avenue des Martyrs, F-38054 Grenoble Cedex 9, France; SHFJ, CEA Orsay, 4 place Général Leclerc, 91401 Orsay Cedex, France; INSERM UMR 970, PARCC, Université Paris Descartes, Sorbonne Paris Cité, France; Assistance Publique des Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Raphaël Boisgard
- SHFJ, CEA Orsay, 4 place Général Leclerc, 91401 Orsay Cedex, France
| | - Pierre-Alain Bayle
- Université Grenoble Alpes, INAC-SCIB, LRM, F-38000 Grenoble, France; CEA, INAC-SCIB, LRM, F-38054 Grenoble, France
| | - Michel Bardet
- Université Grenoble Alpes, INAC-SCIB, LRM, F-38000 Grenoble, France; CEA, INAC-SCIB, LRM, F-38054 Grenoble, France
| | - Bertrand Tavitian
- INSERM UMR 970, PARCC, Université Paris Descartes, Sorbonne Paris Cité, France; Assistance Publique des Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Isabelle Texier
- Université Grenoble Alpes, F-38000 Grenoble, France; CEA-LETI MINATEC/ DTBS, 17 avenue des Martyrs, F-38054 Grenoble Cedex 9, France.
| |
Collapse
|
353
|
Murugan K, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int J Nanomedicine 2015; 10:2191-206. [PMID: 25834433 PMCID: PMC4370919 DOI: 10.2147/ijn.s75615] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Cellular internalization and trans-barrier transport of nanoparticles can be manipulated on the basis of the physicochemical and mechanical characteristics of nanoparticles. Research has shown that these factors significantly influence the uptake of nanoparticles. Dictating these characteristics allows for the control of the rate and extent of cellular uptake, as well as delivering the drug-loaded nanosystem intra-cellularly, which is imperative for drugs that require a specific cellular level to exert their effects. Additionally, physicochemical characteristics of the nanoparticles should be optimal for the nanosystem to bypass the natural restricting phenomena of the body and act therapeutically at the targeted site. The factors at the focal point of emerging smart nanomedicines include nanoparticle size, surface charge, shape, hydrophobicity, surface chemistry, and even protein and ligand conjugates. Hence, this review discusses the mechanism of internalization of nanoparticles and ideal nanoparticle characteristics that allow them to evade the biological barriers in order to achieve optimal cellular uptake in different organ systems. Identifying these parameters assists with the progression of nanomedicine as an outstanding vector of pharmaceuticals.
Collapse
Affiliation(s)
- Karmani Murugan
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Yahya E Choonara
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Pradeep Kumar
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Divya Bijukumar
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Lisa C du Toit
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Viness Pillay
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
354
|
Valiante S, Falanga A, Cigliano L, Iachetta G, Busiello RA, La Marca V, Galdiero M, Lombardi A, Galdiero S. Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats. Int J Nanomedicine 2015; 10:1885-98. [PMID: 25792823 PMCID: PMC4364164 DOI: 10.2147/ijn.s77734] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Peptide gH625, derived from glycoprotein H of herpes simplex virus type 1, can enter cells efficiently and deliver a cargo. Nanoparticles armed with gH625 are able to cross an in vitro model of the blood-brain barrier (BBB). In the present study, in vitro experiments were performed to investigate whether gH625 can enter and accumulate in neuron and astrocyte cell lines. The ability of gH625 to cross the BBB in vivo was also evaluated. gH625 was administered in vivo to rats and its presence in the liver and in the brain was detected. Within 3.5 hours of intravenous administration, gH625 can be found beyond the BBB in proximity to cell neurites. gH625 has no toxic effects in vivo, since it does not affect the maximal oxidative capacity of the brain or the mitochondrial respiration rate. Our data suggest that gH625, with its ability to cross the BBB, represents a novel nanocarrier system for drug delivery to the central nervous system. These results open up new possibilities for direct delivery of drugs into patients in the field of theranostics and might address the treatment of several human diseases.
Collapse
Affiliation(s)
| | - Annarita Falanga
- Department of Pharmacy, University of Naples Federico II, Naples, Italy ; DFM Scarl, University of Naples Federico II, Naples, Italy
| | - Luisa Cigliano
- Department of Biology, University of Naples Federico II, Naples, Italy
| | | | | | - Valeria La Marca
- Department of Biology, University of Naples Federico II, Naples, Italy
| | | | - Assunta Lombardi
- Department of Biology, University of Naples Federico II, Naples, Italy
| | - Stefania Galdiero
- Department of Biology, University of Naples Federico II, Naples, Italy ; Department of Pharmacy, University of Naples Federico II, Naples, Italy
| |
Collapse
|
355
|
Tsukigawa K, Liao L, Nakamura H, Fang J, Greish K, Otagiri M, Maeda H. Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin. Cancer Sci 2015; 106:270-8. [PMID: 25529761 PMCID: PMC4376435 DOI: 10.1111/cas.12592] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Revised: 12/09/2014] [Accepted: 12/13/2014] [Indexed: 01/13/2023] Open
Abstract
Previously, we prepared a pirarubicin (THP)-encapsulated micellar drug using styrene-maleic acid copolymer (SMA) as the drug carrier, in which active THP was non-covalently encapsulated. We have now developed covalently conjugated SMA-THP (SMA-THP conjugate) for further investigation toward clinical development, because covalently linked polymer-drug conjugates are known to be more stable in circulation than drug-encapsulated micelles. The SMA-THP conjugate also formed micelles and showed albumin binding capacity in aqueous solution, which suggested that this conjugate behaved as a macromolecule during blood circulation. Consequently, SMA-THP conjugate showed significantly prolonged circulation time compared to free THP and high tumor-targeting efficiency by the enhanced permeability and retention (EPR) effect. As a result, remarkable antitumor effect was achieved against two types of tumors in mice without apparent adverse effects. Significantly, metastatic lung tumor also showed the EPR effect, and this conjugate reduced metastatic tumor in the lung almost completely at 30 mg/kg once i.v. (less than one-fifth of the maximum tolerable dose). Although SMA-THP conjugate per se has little cytotoxicity in vitro (1/100 of free drug THP), tumor-targeted accumulation by the EPR effect ensures sufficient drug concentrations in tumor to produce an antitumor effect, whereas toxicity to normal tissues is much less. These findings suggest the potential of SMA-THP conjugate as a highly favorable candidate for anticancer nanomedicine with good stability and tumor-targeting properties in vivo.
Collapse
Affiliation(s)
- Kenji Tsukigawa
- Institute for Drug Delivery Science, Sojo University, Kumamoto, Japan; Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
| | | | | | | | | | | | | |
Collapse
|
356
|
Tse BWC, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling MT, Khatri A, Liu T, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine (Lond) 2015; 10:375-86. [DOI: 10.2217/nnm.14.122] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Aim: To evaluate the potential of newly-developed, biocompatible iron oxide magnetic nanoparticles (MNPs) conjugated with J591, an antibody to an extracellular epitope of PSMA, to enhance MRI of prostate cancer. Materials & methods: Specific binding to PSMA by J591-MNP was investigated in vitro. MRI studies were performed on orthotopic tumor-bearing NOD.SCID mice 2 h and 24 h after intravenous injection of J591-MNPs, or non-targeting MNPs. Results & conclusion: In vitro, MNPs did not affect prostate cancer cell viability, and conjugation to J591 did not compromise antibody specificity and enhanced cellular iron uptake. Magnetic resonance contrast of tumors was increased in vivo using PSMA-targeting MNPs, but not by non-targeting MNPs. This provides proof-of-concept that PSMA-targeting MNPs have potential to enhance magnetic resonance detection/localization of prostate cancer.
Collapse
Affiliation(s)
- Brian Wan-Chi Tse
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Gary J Cowin
- National Imaging Facility, Centre for Advanced Imaging, University of Queensland, Brisbane, Queensland, Australia
| | - Carolina Soekmadji
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Lidija Jovanovic
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Raja S Vasireddy
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Ming-Tat Ling
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| | - Aparajita Khatri
- Ceramisphere Pty Ltd (Health Care Division), Sydney, New South Wales, Australia
| | - Tianqing Liu
- Ian Wark Institute, University of South Australia, Adelaide, South Australia, Australia
| | - Benjamin Thierry
- Ian Wark Institute, University of South Australia, Adelaide, South Australia, Australia
| | - Pamela J Russell
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health & Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia
| |
Collapse
|
357
|
Talelli M, Barz M, Rijcken CJ, Kiessling F, Hennink WE, Lammers T. Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical Translation. NANO TODAY 2015; 10:93-117. [PMID: 25893004 PMCID: PMC4398985 DOI: 10.1016/j.nantod.2015.01.005] [Citation(s) in RCA: 351] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Polymeric micelles (PM) are extensively used to improve the delivery of hydrophobic drugs. Many different PM have been designed and evaluated over the years, and some of them have steadily progressed through clinical trials. Increasing evidence suggests, however, that for prolonged circulation times and for efficient EPR-mediated drug targeting to tumors and to sites of inflammation, PM need to be stabilized, to prevent premature disintegration. Core-crosslinking is among the most popular methods to improve the in vivo stability of PM, and a number of core-crosslinked polymeric micelles (CCPM) have demonstrated promising efficacy in animal models. The latter is particularly true for CCPM in which (pro-) drugs are covalently entrapped. This ensures proper drug retention in the micelles during systemic circulation, efficient drug delivery to pathological sites via EPR, and tailorable drug release kinetics at the target site. We here summarize recent advances in the CCPM field, addressing the chemistry involved in preparing them, their in vitro and in vivo performance, potential biomedical applications, and guidelines for efficient clinical translation.
Collapse
Affiliation(s)
- Marina Talelli
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
- Department of Immunology and Oncology and NanoBiomedicine Initiative, Centro Nacional de Biotecnología (CNB)/CSIC, Darwin 3, Cantoblanco, 28049 Madrid, Spain
| | - Matthias Barz
- Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany
| | | | - Fabian Kiessling
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany
| | - Wim E. Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Twan Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany
- Department of Controlled Drug Delivery, University of Twente and MIRA Institute for Biomedical Technology and Technical Medicine, Enschede, The Netherlands
| |
Collapse
|
358
|
Frère A, Kawalec M, Tempelaar S, Peixoto P, Hendrick E, Peulen O, Evrard B, Dubois P, Mespouille L, Mottet D, Piel G. Impact of the Structure of Biocompatible Aliphatic Polycarbonates on siRNA Transfection Ability. Biomacromolecules 2015; 16:769-79. [DOI: 10.1021/bm501676p] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
| | - Michal Kawalec
- Laboratory
of Polymeric and Composite Materials, Center of Innovation and Research
in Materials and Polymers (CIRMAP), Research Institute for Health
Sciences and Technology, University of Mons, Place du Parc 20 - 7000, Mons, Belgium
| | - Sarah Tempelaar
- Laboratory
of Polymeric and Composite Materials, Center of Innovation and Research
in Materials and Polymers (CIRMAP), Research Institute for Health
Sciences and Technology, University of Mons, Place du Parc 20 - 7000, Mons, Belgium
| | | | | | | | | | - Philippe Dubois
- Laboratory
of Polymeric and Composite Materials, Center of Innovation and Research
in Materials and Polymers (CIRMAP), Research Institute for Health
Sciences and Technology, University of Mons, Place du Parc 20 - 7000, Mons, Belgium
| | - Laetitia Mespouille
- Laboratory
of Polymeric and Composite Materials, Center of Innovation and Research
in Materials and Polymers (CIRMAP), Research Institute for Health
Sciences and Technology, University of Mons, Place du Parc 20 - 7000, Mons, Belgium
| | | | | |
Collapse
|
359
|
Fettiplace MR, Lis K, Ripper R, Kowal K, Pichurko A, Vitello D, Rubinstein I, Schwartz D, Akpa BS, Weinberg G. Multi-modal contributions to detoxification of acute pharmacotoxicity by a triglyceride micro-emulsion. J Control Release 2015; 198:62-70. [PMID: 25483426 PMCID: PMC4293282 DOI: 10.1016/j.jconrel.2014.11.018] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Revised: 11/12/2014] [Accepted: 11/17/2014] [Indexed: 11/16/2022]
Abstract
Triglyceride micro-emulsions such as Intralipid® have been used to reverse cardiac toxicity induced by a number of drugs but reservations about their broad-spectrum applicability remain because of the poorly understood mechanism of action. Herein we report an integrated mechanism of reversal of bupivacaine toxicity that includes both transient drug scavenging and a cardiotonic effect that couple to accelerate movement of the toxin away from sites of toxicity. We thus propose a multi-modal therapeutic paradigm for colloidal bio-detoxification whereby a micro-emulsion both improves cardiac output and rapidly ferries the drug away from organs subject to toxicity. In vivo and in silico models of toxicity were combined to test the contribution of individual mechanisms and reveal the multi-modal role played by the cardiotonic and scavenging actions of the triglyceride suspension. These results suggest a method to predict which drug toxicities are most amenable to treatment and inform the design of next-generation therapeutics for drug overdose.
Collapse
Affiliation(s)
- Michael R Fettiplace
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States; Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States
| | - Kinga Lis
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States; Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States
| | - Richard Ripper
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States; Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States
| | - Katarzyna Kowal
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States; Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States
| | - Adrian Pichurko
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States; Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States
| | - Dominic Vitello
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States
| | - Israel Rubinstein
- Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States; Section of Pulmonary, Critical Care, Sleep and Allergy Medicine, Department of Medicine, University of Illinois College of Medicine, 840 South Wood Street (MC 719), Room 920-N CSB, Chicago, IL 60612, United States
| | - David Schwartz
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States
| | - Belinda S Akpa
- Department of Chemical Engineering, University of Illinois at Chicago, 810 S. Clinton Street, Chicago, IL 60607, United States.
| | - Guy Weinberg
- Department of Anesthesiology, University of Illinois College of Medicine, 1740 West Taylor Street, Suite 3200 W, MC515, Chicago, IL 60612, United States; Research & Development Service, Jesse Brown Veterans Affairs Medical Center, 820 S. Damen Avenue, 60612, United States.
| |
Collapse
|
360
|
Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. ACS NANO 2015; 9:16-30. [PMID: 25469470 DOI: 10.1021/nn5062029] [Citation(s) in RCA: 313] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
The design of nanovaccines capable of triggering effective antitumor immunity requires an understanding of how the immune system senses and responds to threats, including pathogens and tumors. Equally important is an understanding of the mechanisms employed by tumor cells to evade immunity and an appreciation of the deleterious effects that antitumor immune responses can have on tumor growth, such as by skewing tumor cell composition toward immunologically silent tumor cell variants. The immune system and tumors engage in a tug-of-war driven by competition where promoting antitumor immunity or tumor cell death alone may be therapeutically insufficient. Nanotechnology affords a unique opportunity to develop therapeutic compounds than can simultaneously tackle both aspects, favoring tumor eradication. Here, we review the current status of nanoparticle-based immunotherapeutic strategies for the treatment of cancer, ranging from antigen/adjuvant delivery vehicles (to professional antigen-presenting cell types of the immune system) to direct tumor antigen-specific T-lymphocyte-targeting compounds and their combinations thereof.
Collapse
Affiliation(s)
- Kun Shao
- Julia McFarlane Diabetes Research Centre (JMDRC) and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cummings School of Medicine, University of Calgary , Calgary, Alberta T2N 4N1 Canada
| | | | | | | | | | | |
Collapse
|
361
|
Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov 2015; 14:239-47. [PMID: 25598505 DOI: 10.1038/nrd4503] [Citation(s) in RCA: 313] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this field has matured, the notion of targeting has been minimized to the concept of increasing the affinity of a nanoparticle for its target. This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously. This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.
Collapse
Affiliation(s)
- Christopher J Cheng
- 1] Department of Biomedical Engineering, Yale University, New Haven, Connecticut 06511, USA. Present address: Alexion Pharmaceuticals, Cheshire, Connecticut 06410, USA. [2]
| | - Gregory T Tietjen
- 1] Department of Biomedical Engineering, Yale University, New Haven, Connecticut 06511, USA. [2]
| | | | - W Mark Saltzman
- Department of Biomedical Engineering, Yale University, New Haven, Connecticut 06511, USA
| |
Collapse
|
362
|
Shah HS, Joshi SA, Haider A, Kortz U, ur-Rehman N, Iqbal J. Synthesis of chitosan-coated polyoxometalate nanoparticles against cancer and its metastasis. RSC Adv 2015. [DOI: 10.1039/c5ra18489d] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
HeLa cells, before and after treatment with nanoparticles.
Collapse
Affiliation(s)
- Hamid Saeed Shah
- Centre for Advanced Drug Research
- Department of Pharmacy COMSATS Institute of Information Technology
- Abbottabad
- Pakistan
| | - Sachin A. Joshi
- Department of Life Sciences and Chemistry
- Jacobs University
- 28725 Bremen
- Germany
- Dr. K. C. Patel Research and Development Centre
| | - Ali Haider
- Department of Life Sciences and Chemistry
- Jacobs University
- 28725 Bremen
- Germany
| | - Ulrich Kortz
- Department of Life Sciences and Chemistry
- Jacobs University
- 28725 Bremen
- Germany
| | - Nisar ur-Rehman
- Centre for Advanced Drug Research
- Department of Pharmacy COMSATS Institute of Information Technology
- Abbottabad
- Pakistan
| | - Jamshed Iqbal
- Centre for Advanced Drug Research
- Department of Pharmacy COMSATS Institute of Information Technology
- Abbottabad
- Pakistan
| |
Collapse
|
363
|
Abstract
In this review, preparation, characterization and application of various types of SBA-15 as drug delivery agents is investigated.
Collapse
Affiliation(s)
| | - Ghodsi Mohammadi Ziarani
- Department of Chemistry
- Alzahra University
- Tehran
- Iran
- National Laboratory of Pharmaceutical Research
| | - Alireza Badiei
- School of Chemistry
- College of Science
- University of Tehran
- Tehran
- Iran
| |
Collapse
|
364
|
Yu Y, Chen CK, Law WC, Sun H, Prasad PN, Cheng C. A degradable brush polymer–drug conjugate for pH-responsive release of doxorubicin. Polym Chem 2015. [DOI: 10.1039/c4py01194e] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We report the synthesis, characterization andin vitroassessment of a degradable brush polymer–drug conjugate which can enable acid-triggered release of doxorubicin (DOX).
Collapse
Affiliation(s)
- Yun Yu
- Department of Chemical and Biological Engineering
- University at Buffalo
- The State University of New York
- Buffalo
- USA
| | - Chih-Kuang Chen
- Department of Chemical and Biological Engineering
- University at Buffalo
- The State University of New York
- Buffalo
- USA
| | - Wing-Cheung Law
- Institute for Lasers
- Photonics and Biophotonics
- and Department of Chemistry
- University at Buffalo
- The State University of New York
| | - Haotian Sun
- Department of Chemical and Biological Engineering
- University at Buffalo
- The State University of New York
- Buffalo
- USA
| | - Paras N. Prasad
- Institute for Lasers
- Photonics and Biophotonics
- and Department of Chemistry
- University at Buffalo
- The State University of New York
| | - Chong Cheng
- Department of Chemical and Biological Engineering
- University at Buffalo
- The State University of New York
- Buffalo
- USA
| |
Collapse
|
365
|
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2014; 200:138-57. [PMID: 25545217 DOI: 10.1016/j.jconrel.2014.12.030] [Citation(s) in RCA: 1179] [Impact Index Per Article: 117.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Revised: 12/22/2014] [Accepted: 12/23/2014] [Indexed: 12/18/2022]
Abstract
Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.
Collapse
|
366
|
Kinnear C, Burnand D, Clift MJD, Kilbinger AFM, Rothen-Rutishauser B, Petri-Fink A. Polyvinylalkohol als biokompatibles Polymer zur Passivierung von Goldnanostäbchen. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201404100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
367
|
Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. J Control Release 2014; 194:82-91. [DOI: 10.1016/j.jconrel.2014.07.059] [Citation(s) in RCA: 164] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 07/28/2014] [Accepted: 07/30/2014] [Indexed: 01/22/2023]
|
368
|
Chen M, Li YF, Besenbacher F. Electrospun nanofibers-mediated on-demand drug release. Adv Healthc Mater 2014; 3:1721-32. [PMID: 24891134 DOI: 10.1002/adhm.201400166] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Revised: 05/06/2014] [Indexed: 12/21/2022]
Abstract
A living system has a complex and accurate regulation system with intelligent sensor-processor-effector components to enable the release of vital bioactive substances on demand at a specific site and time. Stimuli-responsive polymers mimic biological systems in a crude way where an external stimulus results in a change in conformation, solubility, or alternation of the hydrophilic/hydrophobic balance, and consequently release of a bioactive substance. Electrospinning is a straightforward and robust method to produce nanofibers with the potential to incorporate drugs in a simple, rapid, and reproducible process. This feature article emphasizes an emerging area using an electrospinning technique to generate biomimetic nanofibers as drug delivery devices that are responsive to different stimuli, such as temperature, pH, light, and electric/magnetic field for controlled release of therapeutic substances. Although at its infancy, the mimicry of these stimuli-responsive nanofibers to the function of the living systems includes both the fibrous structural feature and bio-regulation function as an on demand drug release depot. The electrospun nanofibers with extracellular matrix morphology intrinsically guide cellular drug uptake, which will be highly desired to translate the promise of drug delivery for the clinical success.
Collapse
Affiliation(s)
- Menglin Chen
- Interdisciplinary Nanoscience Center; Aarhus University; DK-8000 Aarhus Denmark
| | - Yan-Fang Li
- Interdisciplinary Nanoscience Center; Aarhus University; DK-8000 Aarhus Denmark
| | | |
Collapse
|
369
|
|
370
|
Wang G, Maciel D, Wu Y, Rodrigues J, Shi X, Yuan Y, Liu C, Tomás H, Li Y. Amphiphilic polymer-mediated formation of laponite-based nanohybrids with robust stability and pH sensitivity for anticancer drug delivery. ACS APPLIED MATERIALS & INTERFACES 2014; 6:16687-95. [PMID: 25167168 DOI: 10.1021/am5032874] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The development of pH-sensitive drug delivery nanosystems that present a low drug release at the physiological pH and are able to increase the extent of the release at a lower pH value (like those existent in the interstitial space of solid tumors (pH 6.5) and in the intracellular endolysosomal compartments (pH 5.0)) is very important for an efficient and safe cancer therapy. Laponite (LP) is a synthetic silicate nanoparticle with a nanodisk structure (25 nm in diameter and 0.92 nm in thickness) and negative-charged surface, which can be used for the encapsulation of doxorubicin (DOX, a cationic drug) through electrostatic interactions and exhibit good pH sensitivity in drug delivery. However, the colloidal instability of LP still limits its potential clinical applications. In this study, we demonstrate an elegant strategy to develop stable Laponite-based nanohybrids through the functionalization of its surface with an amphiphile PEG-PLA copolymer by a self-assembly process. The hydrophobic block of PEG-PLA acts as an anchor that binds to the surface of drug-loaded LP nanodisks, maintaining the core structure, whereas the hydrophilic PEG part serves as a protective stealth shell that improves the whole stability of the nanohybrids under physiological conditions. The resulting nanocarriers can effectively load the DOX drug (the encapsulation efficiency is 85%), and display a pH-enhanced drug release behavior in a sustained way. In vitro biological evaluation indicated that the DOX-loaded nanocarriers can be effectively internalized by CAL-72 cells (an osteosarcoma cell line), and exhibit a remarkable higher anticancer cytotoxicity than free DOX. The merits of Laponite/PEG-PLA nanohybrids, such as good cytocompatibility, excellent physiological stability, sustained pH-responsive release properties, and improved anticancer activity, make them a promising platform for the delivery of other therapeutic agents beyond DOX.
Collapse
Affiliation(s)
- Guoying Wang
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira , Campus Universitário da Penteada, 9020-105 Funchal, Portugal
| | | | | | | | | | | | | | | | | |
Collapse
|
371
|
Zhang J, Liu J, Zhao Y, Wang G, Zhou F. Plasma and cellular pharmacokinetic considerations for the development and optimization of antitumor block copolymer micelles. Expert Opin Drug Deliv 2014; 12:263-81. [PMID: 25217414 DOI: 10.1517/17425247.2014.945417] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Clinical application of anticancer drugs is often limited by poor pharmacokinetic profile. The biocompatible and/or biodegradable block copolymer micelles (BCMs) can improve the pharmacokinetic behavior of drugs, thus enhancing antitumor effect. However, there are still many problems that needed to be solved before there is a wide clinical application of BCMs. AREAS COVERED Micelles have been quickly developed recently to deliver hydrophobic antitumor drugs specifically. However, the final therapeutic effect of BCMs is often challenged by many factors in vivo from both plasma and cellular pharmacokinetic view: i) inefficient transport from administration site to tumor tissue; ii) poor penetration into tumor mass; iii) inadequate accumulation in tumor cell; and iv) insufficient intracellular/subcellular release in cells. This review emphasized on the newest methods and solutions based on the main challenges of BCMs application in vivo, and the new problems caused by these methods are also discussed. EXPERT OPINION Different strategies and designs of BCMs can help solve problems in each key step respectively. However, overemphasis on one aspect will result in problems on others. Therefore, a comprehensive consideration is urgently needed to integrate the advantages of each strategy and overcome the disadvantages. Only with thorough understanding and scientific assessments, the desired BCMs are expected to be applied in clinical treatments.
Collapse
Affiliation(s)
- Jingwei Zhang
- China Pharmaceutical University, State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics , 24 Tong Jia Xiang, Nanjing, Jiangsu, 210009 , PR China
| | | | | | | | | |
Collapse
|
372
|
Ruan S, Qian J, Shen S, Zhu J, Jiang X, He Q, Gao H. A simple one-step method to prepare fluorescent carbon dots and their potential application in non-invasive glioma imaging. NANOSCALE 2014; 6:10040-7. [PMID: 25031208 DOI: 10.1039/c4nr02657h] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Fluorescent carbon dots (CD) possess impressive potential in bioimaging because of their low photobleaching, absence of optical blinking and good biocompatibility. However, their relatively short excitation/emission wavelengths restrict their application in in vivo imaging. In the present study, a kind of CD was prepared by a simple heat treatment method using glycine as the only precursor. The diameter of CD was lower than 5 nm, and the highest emission wavelength was 500 nm. However, at 600 nm, there was still a relatively strong fluorescent emission, suggesting CD could be used for in vivo imaging. Additionally, several experiments demonstrated that CD possessed good serum stability and low cytotoxicity. In vitro, CD could be taken up into C6 glioma cells in a time- and concentration-dependent manner, with both endosomes and mitochondria involved. In vivo, CD could be used for non-invasive glioma imaging because of its high accumulation in the glioma site of the brain, which was demonstrated by both in vivo imaging and ex vivo tissue imaging. Furthermore, the fluorescent distribution in tissue slices also showed CD distributed in glioma with high intensity, while with a low intensity in normal brain tissue. In conclusion, CD were prepared using a simple method with relatively long excitation and emission wavelengths and could be used for non-invasive glioma imaging.
Collapse
Affiliation(s)
- Shaobo Ruan
- Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, 610041, Chengdu, China.
| | | | | | | | | | | | | |
Collapse
|
373
|
Novo L, Rizzo LY, Golombek SK, Dakwar GR, Lou B, Remaut K, Mastrobattista E, van Nostrum CF, Jahnen-Dechent W, Kiessling F, Braeckmans K, Lammers T, Hennink WE. Decationized polyplexes as stable and safe carrier systems for improved biodistribution in systemic gene therapy. J Control Release 2014; 195:162-175. [PMID: 25204289 DOI: 10.1016/j.jconrel.2014.08.028] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Revised: 08/12/2014] [Accepted: 08/30/2014] [Indexed: 10/24/2022]
Abstract
Many polycation-based gene delivery vectors show high transfection in vitro, but their cationic nature generally leads to significant toxicity and poor in vivo performance which significantly hampers their clinical applicability. Unlike conventional polycation-based systems, decationized polyplexes are based on hydrophilic and neutral polymers. They are obtained by a 3-step process: charge-driven condensation followed by disulfide crosslinking stabilization and finally polyplex decationization. They consist of a disulfide-crosslinked poly(hydroxypropyl methacrylamide) (pHPMA) core stably entrapping plasmid DNA (pDNA), surrounded by a shell of poly(ethylene glycol) (PEG). In the present paper the applicability of decationized polyplexes for systemic administration was evaluated. Cy5-labeled decationized polyplexes were evaluated for stability in plasma by fluorescence single particle tracking (fSPT), which technique showed stable size distribution for 48 h unlike its cationic counterpart. Upon the incubation of the polymers used for the formation of polyplexes with HUVEC cells, MTT assay showed excellent cytocompatibility of the neutral polymers. The safety was further demonstrated by a remarkable low teratogenicity and mortality activity of the polymers in a zebrafish assay, in great contrast with their cationic counterpart. Near infrared (NIR) dye-labeled polyplexes were evaluated for biodistribution and tumor accumulation by noninvasive optical imaging when administered systemically in tumor bearing mice. Decationized polyplexes exhibited an increased circulation time and higher tumor accumulation, when compared to their cationic precursors. Histology of tumors sections showed that decationized polyplexes induced reporter transgene expression in vivo. In conclusion, decationized polyplexes are a platform for safer polymeric vectors with improved biodistribution properties when systemically administered.
Collapse
Affiliation(s)
- Luís Novo
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Larissa Y Rizzo
- Nanomedicines and Theranostics, Department for Experimental Molecular Imaging, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
| | - Susanne K Golombek
- Nanomedicines and Theranostics, Department for Experimental Molecular Imaging, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
| | - George R Dakwar
- Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmacy, Ghent University, Ghent Research Group on Nanomedicines, Harelbekestraat 72, 9000 Ghent, Belgium
| | - Bo Lou
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Katrien Remaut
- Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmacy, Ghent University, Ghent Research Group on Nanomedicines, Harelbekestraat 72, 9000 Ghent, Belgium
| | - Enrico Mastrobattista
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Cornelus F van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Wilhelm Jahnen-Dechent
- Helmholtz Institute for Biomedical Engineering, Biointerface Laboratory, RWTH Aachen University, Aachen, Germany
| | - Fabian Kiessling
- Nanomedicines and Theranostics, Department for Experimental Molecular Imaging, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
| | - Kevin Braeckmans
- Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmacy, Ghent University, Ghent Research Group on Nanomedicines, Harelbekestraat 72, 9000 Ghent, Belgium.,Centre for Nano- and Biophotonics, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium
| | - Twan Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.,Nanomedicines and Theranostics, Department for Experimental Molecular Imaging, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.,Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| |
Collapse
|
374
|
Turkyilmaz S, Rice DR, Palumbo R, Smith BD. Selective recognition of anionic cell membranes using targeted liposomes coated with zinc(ii)-bis(dipicolylamine) affinity units. Org Biomol Chem 2014; 12:5645-55. [PMID: 24962330 PMCID: PMC4128505 DOI: 10.1039/c4ob00924j] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 06/18/2014] [Indexed: 01/18/2023]
Abstract
Zinc(ii)-bis(dipicolylamine) (Zn2BDPA) coated liposomes are shown to have high recognition selectivity towards vesicle and cell membranes with anionic surfaces. Robust synthetic methods were developed to produce Zn2BDPA-PEG-lipid conjugates with varying PEG linker chain length. One conjugate (Zn2BDPA-PEG2000-DSPE) was used in liposome formulations doped with the lipophilic near-infrared fluorophore DiR. Fluorescence cell microscopy studies demonstrated that the multivalent liposomes selectively and efficiently target bacteria in the presence of healthy mammalian cells and cause bacterial cell agglutination. The liposomes also exhibited selective staining of the surfaces of dead or dying human cancer cells that had been treated with a chemotherapeutic agent.
Collapse
Affiliation(s)
- Serhan Turkyilmaz
- Department of Chemistry and Biochemistry , 236 Nieuwland Science Hall and University of Notre Dame , Notre Dame , IN 46556 , USA .
- Faculty of Pharmacy , Department of Pharmaceutical Chemistry , Istanbul University , 34116 Beyazit , Istanbul , Turkey
| | - Douglas R. Rice
- Department of Chemistry and Biochemistry , 236 Nieuwland Science Hall and University of Notre Dame , Notre Dame , IN 46556 , USA .
| | - Rachael Palumbo
- Department of Chemistry and Biochemistry , 236 Nieuwland Science Hall and University of Notre Dame , Notre Dame , IN 46556 , USA .
| | - Bradley D. Smith
- Department of Chemistry and Biochemistry , 236 Nieuwland Science Hall and University of Notre Dame , Notre Dame , IN 46556 , USA .
| |
Collapse
|
375
|
Wang L, Wang C, Jiao J, Su Y, Cheng X, Huang Z, Liu X, Deng Y. Tolerance-like innate immunity and spleen injury: a novel discovery via the weekly administrations and consecutive injections of PEGylated emulsions. Int J Nanomedicine 2014; 9:3645-57. [PMID: 25120362 PMCID: PMC4128795 DOI: 10.2147/ijn.s66318] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
There has been an increasing interest in the study of the innate immune system in recent years. However, few studies have focused on whether innate immunity can acquire tolerance. Therefore, in this study, we investigated tolerance in the innate immune system via the consecutive weekly and daily injections of emulsions modified with polyethylene glycol (PEG), referred to as PEGylated emulsions (PE). The effects of these injections of PE on pharmacokinetics and biodistribution were studied in normal and macrophage-depleted rats. Additionally, we evaluated the antigenic specificity of immunologic tolerance. Immunologic tolerance against PE developed after 21 days of consecutive daily injections or the fourth week of PE administration. Compared with a single administration, it was observed that the tolerant rats had a lower rate of PE clearance from the blood, which was independent of the stress response. In addition, weekly PE injections caused injury to the spleen. Furthermore, the rats tolerant to PEs with the methoxy group (-OCH3) of PEG, failed to respond to the PEs with a different terminal group of PEG or to non-PEG emulsions. Innate immunity tolerance was induced by PE, regardless of the mode of administration. Further study of this mechanism suggested that monocytes play an essential role in the suppression of innate immunity. These findings provide novel insights into the understanding of the innate immune system.
Collapse
Affiliation(s)
- Long Wang
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Chunling Wang
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Jiao Jiao
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Yuqing Su
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Xiaobo Cheng
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Zhenjun Huang
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Xinrong Liu
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| | - Yihui Deng
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People’s Republic of China
| |
Collapse
|
376
|
Groo AC, Lagarce F. Mucus models to evaluate nanomedicines for diffusion. Drug Discov Today 2014; 19:1097-108. [DOI: 10.1016/j.drudis.2014.01.011] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 12/20/2013] [Accepted: 01/24/2014] [Indexed: 01/25/2023]
|
377
|
Sagnella SM, McCarroll JA, Kavallaris M. Drug delivery: Beyond active tumour targeting. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2014; 10:1131-7. [DOI: 10.1016/j.nano.2014.04.012] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Revised: 04/15/2014] [Accepted: 04/29/2014] [Indexed: 11/16/2022]
|
378
|
Kinnear C, Burnand D, Clift MJD, Kilbinger AFM, Rothen-Rutishauser B, Petri-Fink A. Polyvinyl Alcohol as a Biocompatible Alternative for the Passivation of Gold Nanorods. Angew Chem Int Ed Engl 2014; 53:12613-7. [DOI: 10.1002/anie.201404100] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Indexed: 11/11/2022]
|
379
|
Pensado A, Seijo B, Sanchez A. Current strategies for DNA therapy based on lipid nanocarriers. Expert Opin Drug Deliv 2014; 11:1721-31. [DOI: 10.1517/17425247.2014.935337] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Andrea Pensado
- University of Santiago de Compostela, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
Campus Vida, 15782 Santiago de Compostela, Spain
| | - Begoña Seijo
- University of Santiago de Compostela, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
Campus Vida, 15782 Santiago de Compostela, Spain
- Health Research Institute-University Clinical Hospital of Santiago de Compostela (IDIS), Molecular Image Group,
A Choupana, 15706 Santiago de Compostela, Spain
| | - Alejandro Sanchez
- University of Santiago de Compostela, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
Campus Vida, 15782 Santiago de Compostela, Spain
- Health Research Institute-University Clinical Hospital of Santiago de Compostela (IDIS), Molecular Image Group,
A Choupana, 15706 Santiago de Compostela, Spain
| |
Collapse
|
380
|
Abstract
This review article covers the synthetic strategies, structural aspects, and host-guest properties of ruthenium metalla-assemblies, with a special focus on their use as drug delivery vectors. The two-dimensional metalla-rectangles show interesting host-guest possibilities but seem less appropriate for being used as drug carriers. On the other hand, metalla-prisms allow encapsulation and possible targeted release of bioactive molecules and consequently show some potential as drug delivery vectors. The reactivity of these metalla-prisms can be fine-tuned to allow a fine control of the guest’s release. The larger metalla-cubes can be used to stabilize the formation of G-quadruplex DNA and can be used to encapsulate and release photoactive molecules such as porphins. These metalla-assemblies demonstrate great prospective in photodynamic therapy.
Collapse
|
381
|
Conde J, Dias JT, Grazú V, Moros M, Baptista PV, de la Fuente JM. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem 2014; 2:48. [PMID: 25077142 PMCID: PMC4097105 DOI: 10.3389/fchem.2014.00048] [Citation(s) in RCA: 224] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 06/24/2014] [Indexed: 01/04/2023] Open
Abstract
In the last 30 years we have assisted to a massive advance of nanomaterials in material science. Nanomaterials and structures, in addition to their small size, have properties that differ from those of larger bulk materials, making them ideal for a host of novel applications. The spread of nanotechnology in the last years has been due to the improvement of synthesis and characterization methods on the nanoscale, a field rich in new physical phenomena and synthetic opportunities. In fact, the development of functional nanoparticles has progressed exponentially over the past two decades. This work aims to extensively review 30 years of different strategies of surface modification and functionalization of noble metal (gold) nanoparticles, magnetic nanocrystals and semiconductor nanoparticles, such as quantum dots. The aim of this review is not only to provide in-depth insights into the different biofunctionalization and characterization methods, but also to give an overview of possibilities and limitations of the available nanoparticles.
Collapse
Affiliation(s)
- João Conde
- Harvard-MIT Division for Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of TechnologyCambridge, MA, USA
| | - Jorge T. Dias
- Nanotherapy and Nanodiagnostics Group, Instituto de Nanociencia de Aragon, Universidad de ZaragozaZaragoza, Spain
| | - Valeria Grazú
- Nanotherapy and Nanodiagnostics Group, Instituto de Nanociencia de Aragon, Universidad de ZaragozaZaragoza, Spain
| | - Maria Moros
- Nanotherapy and Nanodiagnostics Group, Instituto de Nanociencia de Aragon, Universidad de ZaragozaZaragoza, Spain
| | - Pedro V. Baptista
- CIGMH, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de LisboaCaparica, Portugal
| | - Jesus M. de la Fuente
- Nanotherapy and Nanodiagnostics Group, Instituto de Nanociencia de Aragon, Universidad de ZaragozaZaragoza, Spain
- Fundacion ARAIDZaragoza, Spain
- Key Laboratory for Thin Film and Microfabrication Technology of the Ministry of Education, Department of Bio-Nano Science and Engineering, Institute of Nano Biomedicine and Engineering, Research Institute of Translation Medicine, Shanghai Jiao Tong UniversityShanghai, China
| |
Collapse
|
382
|
Fan Y, Sun Q, Gu H, Li W, Chen Y, Wang J, Zhou N, Xiao Y. GO-COO-HP-β-CD nanosphere: a complex construction and its drug-loading properties. NANOTECHNOLOGY 2014; 25:255601. [PMID: 24896800 DOI: 10.1088/0957-4484/25/25/255601] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A novel nanosphere based on carboxylated GO (GO-COOH) and hydroxypropyl-beta-CD (HP-β-CD) was synthesized to construct a complex of GO-COO-HP-β-CD. The complex formation process was studied using spectral characterization and transmission electron microscopy (TEM). X-ray diffraction and energy dispersive spectroscopy patterns show that HP-β-CD molecules either cover or intercalate into GO-COOH interlayers in the complex. Fourier transform infrared spectroscopy results indicate that GO-COOH and HP-β-CD are linked with covalent bonds formed via esterification. When employed as nanohybrid drug carriers for dexamethasone, the inclusion displays good dispersibility validated by dynamic light scattering (DLS). Cytotoxicity assays and hemolysis testing demonstrate that the nanospheres possess good biological compatibility. The loading capacity of dexamethasone is as high as 32.33%, with loading efficiency 64.66%.
Collapse
Affiliation(s)
- Yunting Fan
- Jiangsu Key Laboratory of Biofunctional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, People's Republic of China. Jiangsu Engineering Research Center for Biomedical Functional Materials, Nanjing Normal University, Nanjing 210023, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
383
|
Grassi M, Grassi G. Application of mathematical modeling in sustained release delivery systems. Expert Opin Drug Deliv 2014; 11:1299-321. [PMID: 24938598 DOI: 10.1517/17425247.2014.924497] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION This review, presenting as starting point the concept of the mathematical modeling, is aimed at the physical and mathematical description of the most important mechanisms regulating drug delivery from matrix systems. The precise knowledge of the delivery mechanisms allows us to set up powerful mathematical models which, in turn, are essential for the design and optimization of appropriate drug delivery systems. AREAS COVERED The fundamental mechanisms for drug delivery from matrices are represented by drug diffusion, matrix swelling, matrix erosion, drug dissolution with possible recrystallization (e.g., as in the case of amorphous and nanocrystalline drugs), initial drug distribution inside the matrix, matrix geometry, matrix size distribution (in the case of spherical matrices of different diameter) and osmotic pressure. Depending on matrix characteristics, the above-reported variables may play a different role in drug delivery; thus the mathematical model needs to be built solely on the most relevant mechanisms of the particular matrix considered. EXPERT OPINION Despite the somewhat diffident behavior of the industrial world, in the light of the most recent findings, we believe that mathematical modeling may have a tremendous potential impact in the pharmaceutical field. We do believe that mathematical modeling will be more and more important in the future especially in the light of the rapid advent of personalized medicine, a novel therapeutic approach intended to treat each single patient instead of the 'average' patient.
Collapse
Affiliation(s)
- Mario Grassi
- University of Trieste, Department of Engineering and Architecture , Via Valerio 6/A, I - 34127, Trieste , Italy +39 040 558 3435 ; +39 040 569823 ;
| | | |
Collapse
|
384
|
van der Weijden J, Paulis LE, Verdoes M, van Hest JCM, Figdor CG. The right touch: design of artificial antigen-presenting cells to stimulate the immune system. Chem Sci 2014. [DOI: 10.1039/c4sc01112k] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
|
385
|
Zhang P, Huang Y, Liu H, Marquez RT, Lu J, Zhao W, Zhang X, Gao X, Li J, Venkataramanan R, Xu L, Li S. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials 2014; 35:7146-56. [PMID: 24856103 DOI: 10.1016/j.biomaterials.2014.04.108] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Accepted: 04/28/2014] [Indexed: 12/18/2022]
Abstract
We report here that a simple, well-defined, and easy-to-scale up nanocarrier, PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 conjugate (PEG-Fmoc), provides high loading capacity, excellent formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic agent for various types of cancers. 9-Fluorenylmethoxycarbonyl (Fmoc) was incorporated into the nanocarrier as a functional building block to interact with drug molecules. PEG-Fmoc was synthesized via a three-step synthetic route, and it readily interacted with PTX to form mixed nanomicelles of small particle size (25-30 nm). The PTX loading capacity was about 36%, which stands well among the reported micellar systems. PTX entrapment in this micellar system is achieved largely via an Fmoc/PTX π-π stacking interaction, which was demonstrated by fluorescence quenching studies and (13)C NMR. PTX formulated in PEG-Fmoc micelles demonstrated sustained release kinetics, and in vivo distribution study via near infrared fluorescence imaging demonstrated an effective delivery of Cy5.5-labled PTX to tumor sites. The maximal tolerated dose for PTX/PEG-Fmoc (MTD > 120 mg PTX/kg) is higher than those for most reported PTX formulations, and in vivo therapeutic study exhibited a significantly improved antitumor activity than Taxol, a clinically used formulation of PTX. Our system may hold promise as a simple, safe, and effective delivery system for PTX with a potential for rapid translation into clinical study.
Collapse
Affiliation(s)
- Peng Zhang
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Yixian Huang
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Hao Liu
- Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA; Department of Radiation Oncology, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA
| | - Rebecca T Marquez
- Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA; Department of Radiation Oncology, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA
| | - Jianqin Lu
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Wenchen Zhao
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Xiaolan Zhang
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Xiang Gao
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Jiang Li
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Raman Venkataramanan
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Liang Xu
- Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA; Department of Radiation Oncology, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA
| | - Song Li
- Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA.
| |
Collapse
|
386
|
Wang X, Li S, Wan Z, Quan Z, Tan Q. Investigation of thermo-sensitive amphiphilic micelles as drug carriers for chemotherapy in cholangiocarcinoma in vitro and in vivo. Int J Pharm 2014; 463:81-8. [DOI: 10.1016/j.ijpharm.2013.12.046] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Revised: 12/19/2013] [Accepted: 12/28/2013] [Indexed: 10/25/2022]
|
387
|
Borel T, Sabliov C. Nanodelivery of Bioactive Components for Food Applications: Types of Delivery Systems, Properties, and Their Effect on ADME Profiles and Toxicity of Nanoparticles. Annu Rev Food Sci Technol 2014; 5:197-213. [DOI: 10.1146/annurev-food-030713-092354] [Citation(s) in RCA: 95] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T. Borel
- Department of Biological and Agricultural Engineering, LSU Agricultural Center, Louisiana State University, Baton Rouge, Louisiana 70803;
| | - C.M. Sabliov
- Department of Biological and Agricultural Engineering, LSU Agricultural Center, Louisiana State University, Baton Rouge, Louisiana 70803;
| |
Collapse
|
388
|
|
389
|
Lim JM, Bertrand N, Valencia PM, Rhee M, Langer R, Jon S, Farokhzad OC, Karnik R. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. NANOMEDICINE : NANOTECHNOLOGY, BIOLOGY, AND MEDICINE 2014; 10:401-9. [PMID: 23969105 PMCID: PMC3951970 DOI: 10.1016/j.nano.2013.08.003] [Citation(s) in RCA: 120] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Revised: 07/30/2013] [Accepted: 08/12/2013] [Indexed: 01/05/2023]
Abstract
Microfluidic synthesis of nanoparticles (NPs) can enhance the controllability and reproducibility in physicochemical properties of NPs compared to bulk synthesis methods. However, applications of microfluidic synthesis are typically limited to in vitro studies due to low production rates. Herein, we report the parallelization of NP synthesis by 3D hydrodynamic flow focusing (HFF) using a multilayer microfluidic system to enhance the production rate without losing the advantages of reproducibility, controllability, and robustness. Using parallel 3D HFF, polymeric poly(lactide-co-glycolide)-b-polyethyleneglycol (PLGA-PEG) NPs with sizes tunable in the range of 13-150 nm could be synthesized reproducibly with high production rate. As a proof of concept, we used this system to perform in vivo pharmacokinetic and biodistribution study of small (20 nm diameter) PLGA-PEG NPs that are otherwise difficult to synthesize. Microfluidic parallelization thus enables synthesis of NPs with tunable properties with production rates suitable for both in vitro and in vivo studies. FROM THE CLINICAL EDITOR Applications of nanoparticle synthesis with microfluidic methods are typically limited to in vitro studies due to low production rates. The team of authors of this proof-of-principle study reports on the successful parallelization of NP synthesis by 3D hydrodynamic flow focusing using a multilayer microfluidic system to enhance production rate without losing the advantages of reproducibility, controllability, and robustness.
Collapse
Affiliation(s)
- Jong-Min Lim
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital - Harvard Medical School, Boston, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Nicolas Bertrand
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Pedro M Valencia
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Minsoung Rhee
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital - Harvard Medical School, Boston, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Robert Langer
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Sangyong Jon
- Department of Biological Sciences, KAIST, Daejeon, Republic of Korea
| | - Omid C Farokhzad
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital - Harvard Medical School, Boston, MA, USA.
| | - Rohit Karnik
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
| |
Collapse
|
390
|
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66:2-25. [PMID: 24270007 PMCID: PMC4219254 DOI: 10.1016/j.addr.2013.11.009] [Citation(s) in RCA: 1864] [Impact Index Per Article: 186.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Revised: 10/23/2013] [Accepted: 11/13/2013] [Indexed: 12/17/2022]
Abstract
Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000's. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development. The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated. It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnology can meaningfully contribute to create differentiated products and improve clinical outcome. This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL® and Abraxane®. It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398. It highlights the opportunities and challenges faced by nanomedicines in contemporary oncology, where personalized medicine is increasingly the mainstay of cancer therapy. We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential "retention" in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages. The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.
Collapse
Affiliation(s)
- Nicolas Bertrand
- The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jun Wu
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA
| | - Xiaoyang Xu
- The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA
| | - Nazila Kamaly
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA
| | - Omid C Farokhzad
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA.
| |
Collapse
|
391
|
Gao H, He Q. The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert Opin Drug Deliv 2014; 11:409-20. [DOI: 10.1517/17425247.2014.877442] [Citation(s) in RCA: 107] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
392
|
Kraft JC, Freeling JP, Wang Z, Ho RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014; 103:29-52. [PMID: 24338748 PMCID: PMC4074410 DOI: 10.1002/jps.23773] [Citation(s) in RCA: 352] [Impact Index Per Article: 35.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 10/11/2013] [Accepted: 10/14/2013] [Indexed: 12/13/2022]
Abstract
Liposomes are spherical-enclosed membrane vesicles mainly constructed with lipids. Lipid nanoparticles are loaded with therapeutics and may not contain an enclosed bilayer. The majority of those clinically approved have diameters of 50-300 nm. The growing interest in nanomedicine has fueled lipid-drug and lipid-protein studies, which provide a foundation for developing lipid particles that improve drug potency and reduce off-target effects. Integrating advances in lipid membrane research has enabled therapeutic development. At present, about 600 clinical trials involve lipid particle drug delivery systems. Greater understanding of pharmacokinetics, biodistribution, and disposition of lipid-drug particles facilitated particle surface hydration technology (with polyethylene glycol) to reduce rapid clearance and provide sufficient blood circulation time for drug to reach target tissues and cells. Surface hydration enabled the liposome-encapsulated cancer drug doxorubicin (Doxil) to gain clinical approval in 1995. Fifteen lipidic therapeutics are now clinically approved. Although much research involves attaching lipid particles to ligands selective for occult cells and tissues, preparation procedures are often complex and pose scale-up challenges. With emerging knowledge in drug target and lipid-drug distribution in the body, a systems approach that integrates knowledge to design and scale lipid-drug particles may further advance translation of these systems to improve therapeutic safety and efficacy.
Collapse
Affiliation(s)
- John C Kraft
- Department of Pharmaceutics, University of Washington, Seattle, Washington
| | | | | | | |
Collapse
|
393
|
Chen CK, Law WC, Aalinkeel R, Yu Y, Nair B, Wu J, Mahajan S, Reynolds JL, Li Y, Lai CK, Tzanakakis ES, Schwartz SA, Prasad PN, Cheng C. Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells. NANOSCALE 2014; 6:1567-72. [PMID: 24326457 PMCID: PMC4522154 DOI: 10.1039/c3nr04804g] [Citation(s) in RCA: 86] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Having unique architectural features, cationic polymeric nanocapsules (NCs) with well-defined covalently stabilized biodegradable structures were generated as potentially universal and safe therapeutic nanocarriers. These NCs were synthesized from allyl-functionalized cationic polylactide (CPLA) by highly efficient UV-induced thiol-ene interfacial cross-linking in transparent miniemulsions. With tunable nanoscopic sizes, negligible cytotoxicity and remarkable degradability, they are able to encapsulate doxorubicin (Dox) with inner cavities and bind interleukin-8 (IL-8) small interfering RNA (siRNA) with cationic shells. The Dox-encapsulated NCs can effectively bypass the P-glycoprotein (Pgp)-mediated multidrug resistance of MCF7/ADR cancer cells, thereby resulting in increased intracellular drug concentration and reduced cell viability. In vitro studies also showed that the NCs loaded with Dox, IL-8 siRNA and both agents can be readily taken up by PC3 prostate cancer cells, resulting in a significant chemotherapeutic effect and/or IL-8 gene silencing.
Collapse
Affiliation(s)
- Chih-Kuang Chen
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Wing-Cheung Law
- Institute for Lasers, Photonics and Biophotonics, and Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Ravikumar Aalinkeel
- Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University at Buffalo, The State University of New York, Buffalo General Hospital, Buffalo, NY 14203, USA
| | - Yun Yu
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Bindukumar Nair
- Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University at Buffalo, The State University of New York, Buffalo General Hospital, Buffalo, NY 14203, USA
| | - Jincheng Wu
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Supriya Mahajan
- Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University at Buffalo, The State University of New York, Buffalo General Hospital, Buffalo, NY 14203, USA
| | - Jessica L. Reynolds
- Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University at Buffalo, The State University of New York, Buffalo General Hospital, Buffalo, NY 14203, USA
| | - Yukun Li
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Cheng Kee Lai
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Emmanuel S. Tzanakakis
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| | - Stanley A. Schwartz
- Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University at Buffalo, The State University of New York, Buffalo General Hospital, Buffalo, NY 14203, USA
| | - Paras N. Prasad
- Institute for Lasers, Photonics and Biophotonics, and Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
- Department of Chemistry, Korea University, Seoul, 136-701, Korea
| | - Chong Cheng
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
| |
Collapse
|
394
|
Sotiriou GA, Etterlin GD, Spyrogianni A, Krumeich F, Leroux JC, Pratsinis SE. Plasmonic biocompatible silver–gold alloyed nanoparticles. Chem Commun (Camb) 2014; 50:13559-62. [DOI: 10.1039/c4cc05297h] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Nanoalloying Ag with Au minimizes nanoparticle surface oxidation and subsequent toxic Ag+ ion release rendering such nanoparticles safer for theranostic applications.
Collapse
Affiliation(s)
- Georgios A. Sotiriou
- Particle Technology Laboratory
- Institute of Process Engineering
- Department of Mechanical and Process Engineering
- ETH Zurich
- Zurich 8092, Switzerland
| | - Gion Diego Etterlin
- Particle Technology Laboratory
- Institute of Process Engineering
- Department of Mechanical and Process Engineering
- ETH Zurich
- Zurich 8092, Switzerland
| | - Anastasia Spyrogianni
- Particle Technology Laboratory
- Institute of Process Engineering
- Department of Mechanical and Process Engineering
- ETH Zurich
- Zurich 8092, Switzerland
| | - Frank Krumeich
- Particle Technology Laboratory
- Institute of Process Engineering
- Department of Mechanical and Process Engineering
- ETH Zurich
- Zurich 8092, Switzerland
| | - Jean-Christophe Leroux
- Drug Formulation & Delivery
- Institute of Pharmaceutical Sciences
- Department of Chemistry and Applied Biosciences
- ETH Zurich
- Zurich 8093, Switzerland
| | - Sotiris E. Pratsinis
- Particle Technology Laboratory
- Institute of Process Engineering
- Department of Mechanical and Process Engineering
- ETH Zurich
- Zurich 8092, Switzerland
| |
Collapse
|
395
|
Zhang L, Li Y, Yu JC. Chemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatment. J Mater Chem B 2014; 2:452-470. [DOI: 10.1039/c3tb21196g] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
396
|
Nanomedicine: The Promise and Challenges in Cancer Chemotherapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 811:207-33. [DOI: 10.1007/978-94-017-8739-0_11] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
397
|
Upponi JR, Torchilin VP. Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors. NANO-ONCOLOGICALS 2014. [DOI: 10.1007/978-3-319-08084-0_1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
398
|
Alvarez-Lorenzo C, Concheiro A. Smart drug delivery systems: from fundamentals to the clinic. Chem Commun (Camb) 2014; 50:7743-65. [DOI: 10.1039/c4cc01429d] [Citation(s) in RCA: 276] [Impact Index Per Article: 27.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Smart materials can endow implantable depots, targetable nanocarriers and insertable medical devices with activation-modulated and feedback-regulated control of drug release.
Collapse
Affiliation(s)
- Carmen Alvarez-Lorenzo
- Departamento de Farmacia y Tecnología Farmacéutica
- Universidad de Santiago de Compostela
- 15782-Santiago de Compostela, Spain
| | - Angel Concheiro
- Departamento de Farmacia y Tecnología Farmacéutica
- Universidad de Santiago de Compostela
- 15782-Santiago de Compostela, Spain
| |
Collapse
|
399
|
Valencia PM, Pridgen EM, Rhee M, Langer R, Farokhzad OC, Karnik R. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS NANO 2013; 7:10671-80. [PMID: 24215426 PMCID: PMC3963607 DOI: 10.1021/nn403370e] [Citation(s) in RCA: 142] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Taking a nanoparticle (NP) from discovery to clinical translation has been slow compared to small molecules, in part by the lack of systems that enable their precise engineering and rapid optimization. In this work we have developed a microfluidic platform for the rapid, combinatorial synthesis and optimization of NPs. The system takes in a number of NP precursors from which a library of NPs with varying size, surface charge, target ligand density, and drug load is produced in a reproducible manner. We rapidly synthesized 45 different formulations of poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) NPs of different size and surface composition and screened and ranked the NPs for their ability to evade macrophage uptake in vitro. Comparison of the results to pharmacokinetic studies in vivo in mice revealed a correlation between in vitro screen and in vivo behavior. Next, we selected NP synthesis parameters that resulted in longer blood half-life and used the microfluidic platform to synthesize targeted NPs with varying targeting ligand density (using a model targeting ligand against cancer cells). We screened NPs in vitro against prostate cancer cells as well as macrophages, identifying one formulation that exhibited high uptake by cancer cells yet similar macrophage uptake compared to nontargeted NPs. In vivo, the selected targeted NPs showed a 3.5-fold increase in tumor accumulation in mice compared to nontargeted NPs. The developed microfluidic platform in this work represents a tool that could potentially accelerate the discovery and clinical translation of NPs.
Collapse
Affiliation(s)
- Pedro M. Valencia
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Eric M. Pridgen
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Minsoung Rhee
- Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Robert Langer
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
- MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA 02139
- To whom correspondence should be addressed. Omid C. Farokhzad Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115. ; Rohit Karnik Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139. ; Robert Langer Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Omid C. Farokhzad
- Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115
- MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA 02139
- To whom correspondence should be addressed. Omid C. Farokhzad Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115. ; Rohit Karnik Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139. ; Robert Langer Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Rohit Karnik
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
- To whom correspondence should be addressed. Omid C. Farokhzad Laboratory of Nanomedicine and Biomaterials and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115. ; Rohit Karnik Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139. ; Robert Langer Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
| |
Collapse
|
400
|
d'Angelo I, Conte C, Miro A, Quaglia F, Ungaro F. Core–shell nanocarriers for cancer therapy. Part I: biologically oriented design rules. Expert Opin Drug Deliv 2013; 11:283-97. [DOI: 10.1517/17425247.2014.868881] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|